![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Coronavirus._SARS-CoV-2.png/640px-Coronavirus._SARS-CoV-2.png&w=640&q=50)
Sinopharm WIBP COVID-19 vaccine
Vaccine against COVID-19 / From Wikipedia, the free encyclopedia
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV,[1][2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[3] The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.
For other uses, see Sinopharm COVID-19 vaccine.
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Zhongkangkewei (Chinese: 众康可维) |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Close